On-Demand version of the February 8, 2018 eCast.
Please note: This is a Single Viewer On-Demand eCast available for one registrant to access the on-demand version of the eCast. Once registered, access is granted via the AABB Education Website located at http://education.aabb.org.
Learning ObjectivesAfter participating in this educational activity, participants should be able to:
· Understand the steps involved with producing CAR T cells.
· List the reason why too few autologous T cells are collected or too few CAR T cells are produced.
· Discuss methods being used to ensure that an adequate quantity of CD3+ cells are collected
· Understand modifications being made to the CAR T cells manufacturing process to improve manufacturing yields
Chimeric Antigen Receptor (CAR) T cells are an important immerging new cancer immunotherapy. They have been found to be clinically effective for many types of hematological cancers and the clinical application of these therapies is growing rapidly. Typically, CAR T cell therapies are made from autologous peripheral blood mononuclear cells (PBMC) collected by apheresis; the cells are produced at a centralized manufacturing facility; and the final CAR T cell product is shipped to an academic health center where it is infused. However, PBMC collection and CAR T cell manufacturing are not always successful.
Two experts will present their work related to the collection of autologous PBMC concentrates and the manufacture of CAR T cells. The typical collection and manufacturing process will be discussed as will common problems associated with PBMC collection and CAR T cell production. Methods that are being used to ensure enough autologous T cells are collected and sufficient quantities of transduced T cells are produced will be reviewed.